FDA OKs new use for Regeneron and Sanofi’s Dupixent

Regeneron Pharmaceuticals (REGN -2.3%) and commercialization partner Sanofi (SNY -0.6%) announce the FDA nod for Dupixent (dupilumab) for the treatment of adults with uncontrolled chronic rhinosinusitis with nasal polyposis. The agency assessed the application under Priority Review status.

The FDA first approved the IL-4 receptor alpha antagonist in May 2017 for eczema, followed by approvals for asthma in October 2018 and atopic dermatitis in March of this year.

https://seekingalpha.com/news/3474024-fda-oks-new-use-regeneron-sanofis-dupixent